Therefore, glioma cases with cytosolic ROS1 fusions could be proposed to possess greater opportunities to be given appropriate chemotherapy other than the current standard treatment using the alkylating agent temozolomide [48]. This evidence concerns the gene ROS1 and central nervous system cancer.